Medicinal Fungi Evidence Update

Peer-reviewed · published 26 September and newly indexed 16 October. Design: single-arm pre/post proof-of-concept study; 10 healthy nonsmoking adults aged 18–55 completed 28 days. There was no placebo, no concurrent control and no prospective registry reported.

Outcomes. NIH Toolbox Flanker Inhibitory Control and Attention, Dimensional Change Card Sort, and plasma BDNF. Every pre/post comparison was nonsignificant (all p>0.05). Reported effect sizes (d=0.48, 0.25 and 0.31) are uncontrolled and highly unstable at n=10; they should not be converted into an efficacy signal.

Bias and relevance. Tiny sample, no comparator, practice effects and regression to the mean unresolved. The product was supplied by M2 Ingredients; funding came from an unrestricted International Society of Sports Nutrition grant. Several authors disclosed supplement-industry or consultancy ties. The demographic table also lists an unexplained second group of 10, despite the methods and results describing only one 10-person cohort.

Peer-reviewed Bayesian network meta-analysis · published 16 October; 31 RCTs and 2,604 participants across three Chinese patent medicines. The medicinal-fungi-relevant node was Huaier granule plus transarterial chemoembolisation (TACE), compared only through the common TACE-alone node.

Exact intervention. Huaier granule, described as a Chinese patent medicine based on an aqueous extract of Trametes robiniophila (also reported as Vanderbylia robiniophila), added to TACE. The review did not establish a common fungal strain, source material, manufacturing specification or dose across the included trials. TACE and supportive-care protocols also varied. Conclusions therefore belong to the included Huaier-granule regimens, not Huaier fungus or turkey-tail products broadly.

Results. Objective response favoured Huaier plus TACE over TACE alone (OR 1.47, 95% credible interval 1.05–2.05). Disease control was null (OR 1.12, 0.66–1.91). Survival evidence was sparse (four studies across all products) and nonsignificant. No head-to-head medicine comparisons existed, so treatment rankings were wholly indirect.

Quality. 31 small Chinese trials (19–116 participants), no blinded trial and only one with allocation concealment. Nineteen merely stated that randomisation occurred. The paper's survival/adverse-event tables appear to label negative log-odds values as odds ratios, a reporting problem. Funnel-plot symmetry does not rule out publication bias in a small, geographically concentrated literature. PROSPERO CRD420251019361; no funding or conflicts declared.

Replication context. This is not an independent new trial and likely overlaps the older RCTs pooled in the Huaier meta-analysis logged on 25 September. It refines the synthesis rather than independently reproducing efficacy.

Peer-reviewed PNAS study · online 20 October. Model: female BALB/c mice (n=10/group) challenged intranasally with 10⁸ CCU Mycoplasma pneumoniae. Oral GLFP2 was given at 200 or 400 mg/kg/day, beginning two days before infection and continuing for seven days; azithromycin 20 mg/kg/day was the positive comparator.

Results and causal strength. GLFP2 reduced lung injury, pathogen burden and inflammatory markers. More importantly, gut-microbiota-derived extracellular vesicles (GMEVs) from treated mice transferred protection to recipients, reached the lung and were taken up by alveolar macrophages. Degradation work linked activity to the beta-(1,6)-galactosyl motif; downstream data supported AMPK activation and S100A8/A9 suppression. This is stronger than pathway correlation alone.

Limits. One laboratory; one sex; high oral doses; preventive dosing started before infection; no human data and no independent replication. The authors declared no competing interests and reported public Chinese funding, but the same institution/authors have an active patent covering GLFP2 and its use, which is a translational-interest consideration.